CoronaryAtlas logo
CoronaryAtlas
CD14
Pathway / Plaque inflammation

CD14

CD14protein

CD14 marks monocyte and macrophage subsets that drive vascular inflammation, plaque destabilization, and contribute to platelet–leukocyte crosstalk during acute coronary thrombosis.

Pathway placement
Cascade stepPlaque inflammation
Confidencehigh
RationaleMonocyte/macrophage activation marker; inflammatory subset in plaque destabilization.
Also acts inPlatelet activation
Druggability
DruggableYes
Known drugs / candidates2
Small-molecule tractableYes
Antibody tractableYes
EnsemblENSG00000170458

Type I vs Type II discrimination

ScoresShared / rises in both
R — rupture / Type-I
67
C — confounder / Type-II
56
A — assay feasibility
72
E — evidence strength
52
T1DI (composite)
21
Specificity differential (R−C)+11.1
Confounder panel (Type-II drivers)
1sepsis / systemic inflammationmag 2
2anemia / acute blood lossn/a
3hypovolemia / dehydrationn/a
4tachyarrhythmiamag 1
5hypoxemia / respiratory failuren/a
6hypertensive emergencyn/a
7high-demand / peri-operative stressmag 2
Coverage: 3/7 confounders with evidence
Tier: deep-scored (abstract-extracted) · 8 supporting references. See the discrimination table for all markers.

Assay & specimen

Class-level default (no specific cleared assay)— generic method inferred from analyte class; confirm against a specific product insert before use.
Specimen
Serum or plasma
Collection tube
Serum separator (gold/red-top, SST) · K2/K3-EDTA (lavender-top)
Method / principle
Sandwich immunoassay (ELISA) — research-grade unless a cleared assay exists
Reagent / substrate
Matched anti-target antibody pair (capture + labeled detection)
Platform
ELISA microplate or multiplex (Luminex/MSD)
Turnaround · availability
Send-out / research · Research-grade (no universal clinical assay)

Human genetic evidence

0.061
Open Targets association (STEMI)

Literature evidence(9)

Omics datasets(1)